Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?

Eli Lilly has surged over 50% in the past year with 39% revenue growth driven by its GLP-1 drugs Zepbound and Mounjaro, but trades at a steep 45x P/E ratio. Novo Nordisk has lagged with only 6% revenue growth but trades at just 10x earnings and could see significant upside if its higher-dose Wegovy gains traction. The author favors Novo Nordisk as the better value play despite Eli Lilly's superior growth, citing valuation concerns and increased competition ahead.